Maverick Therapeutics

10 articles about Maverick Therapeutics

• Maverick Therapeutics Announces Key Executive Promotion and Scientific Advisory Board Appointments to Further Prepare for Clinical Development in 2021

  8/31/2020

  Maverick Therapeutics, Inc., a private biopharmaceutical company pioneering conditionally active bispecific T cell targeted immunotherapies, today announced the promotion of Jeremiah Degenhardt, Ph.D. to Vice President, Translational Oncology & Bioinformatics, as well as the appointment of three immuno-oncology experts to its Scientific Advisory Board.

• Maverick Therapeutics Reveals Preclinical Data from COBRA™ Program, MVC-280, at Virtual Cell Engager Summit 2020

  8/19/2020

  Maverick Therapeutics, Inc., a private biopharmaceutical company pioneering conditionally active bispecific T cell targeted immunotherapies, today announced the presentation of preclinical data from its lead COBRA™ programs, MVC-101 and MVC-280, at the 2 nd Annual Cell Engager Summit taking place virtually from August 18 to August 20, 2020. Chad May Ph.D., Senior Vice President, Research & Development, Maveric

• Maverick Therapeutics Announces First Peer-Reviewed Publication Describing the Design and Development of the COBRA™ Platform

  8/6/2020

  Maverick Therapeutics, Inc., a private biopharmaceutical company pioneering conditionally active bispecific T cell targeted immunotherapies, today announced the publication of a peer-reviewed article in mAbs, a leading journal focused on the science of antibody research and development. The article, titled “COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors,” establis

• Maverick Therapeutics Announces Pipeline Updates for its Conditionally Active T Cell Engaging COBRA™ Platform at the Jefferies Virtual Global Healthcare Conference

  6/3/2020

  Maverick Therapeutics Announces Pipeline Updates for its Conditionally Active T Cell Engaging COBRA ™ Platform at the Jefferies Virtual Global Healthcare Conference - MVC-101 is an EGFR x CD3 COBRA for the treatment of patients with EGFR-expressing solid tumor cancers via weekly dosing - - MVC-280 is a B7H3 x CD3 COBRA for the treatment of patients with B7H3-expressing solid tumor cancers via weekly dosing - - Both programs are scheduled for cli

• Maverick Therapeutics to Participate at 2020 Jefferies Virtual Healthcare Conference

  5/27/2020

  Maverick Therapeutics Inc., a private biopharmaceutical company pioneering conditionally active bispecific T cell targeted immunotherapies, today announced it will share company and pipeline updates at the Jefferies Virtual Healthcare Conference being held from June 2 to June 4, 2020. Chief Executive Officer Jim Scibetta is scheduled to participate in a live presentation on June 3, 2020 at 3:30 p.m. Eastern Time. Fo

• Maverick Therapeutics to Unveil Pre-Clinical Data on Novel COBRATM Platform at American Association for Cancer Research 2019 Annual Meeting

  3/30/2019

  Pre-clinical Data Characterize the Conditional and Potent Activity of the Company’s Novel COBRATM Platform, a Conditionally Active T-cell Engaging Therapeutic Designed to Target Solid Tumors

• 

  BioSpace Movers and Shakers: Feb. 1

  2/1/2019

  As January ends, biotech and pharma companies tap new leaders to help drive strategic visions. New hires at Histogen, Indalo, Novartis Oncology, Calico, and more.

• Ex-Pacira Exec Joins Bay Area Maverick Therapeutics as CEO

  8/10/2017

• Isogenica Limited Announces New Licence Agreement With Maverick Therapeutics

  2/6/2017

• Takeda Takes a $125 Million+ Chance, Seals an Option to Buy Bay Area Startup Maverick Therapeutics

  1/12/2017